<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85155">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01996644</url>
  </required_header>
  <id_info>
    <org_study_id>201212062</org_study_id>
    <secondary_id>F31MH096433-01</secondary_id>
    <nct_id>NCT01996644</nct_id>
  </id_info>
  <brief_title>A Double Blind Clinical Trial of DCS for Food Anxiety</brief_title>
  <official_title>A Double Blind Clinical Trial of DCS for Food Anxiety for Patients With Anorexia and Bulimia Nervosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study investigating if cycloserine (DCS; a learning enhancement medication)
      augments exposure therapy for food anxiety in patients with anorexia and bulimia nervosa.
      The investigators expect that (a) exposure therapy will reduce anxiety (b) anxiety will be
      reduced more in the DCS relative to placebo condition (c) participants in the DCS condition
      will have a greater increase in Body Mass Index.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anxiety</measure>
    <time_frame>Twice a week for two weeks</time_frame>
    <description>Anxiety will be measured at 4 sessions, twice a week for two weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>twice a week for two weeks and at initial assessment</time_frame>
    <description>BMI will be measured twice a week for two weeks and once before starting the trial.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fear of food</measure>
    <time_frame>Twice during 2 weeks</time_frame>
    <description>Fear of food will be measured once before and after the trial.</description>
  </other_outcome>
  <other_outcome>
    <measure>SUDS</measure>
    <time_frame>2 weeks- twice a week</time_frame>
    <description>SUDS will be measured twice a week for two weeks during trial.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Anorexia and Bulimia Nervosa</condition>
  <arm_group>
    <arm_group_label>Setraline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250 mg DCS (setraline) versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertaline</intervention_name>
    <arm_group_label>Setraline</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>D-Cycloserine</other_name>
    <other_name>Cycloserine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with Anorexia Nervosa, Bulimia Nervosa, Eating Disorder Not Otherwise
             Specified

        Exclusion Criteria:

          -  Pregnant or planning on becoming pregnant

          -  Psychotic or Manic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>December 9, 2014</lastchanged_date>
  <firstreceived_date>November 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anorexia, Bulimia, Eating disorder, Anxiety, Exposure Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Bulimia</mesh_term>
    <mesh_term>Bulimia Nervosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
